EC approves lazertinib in combination with amivantamab for NSCLC patients
21st January 2025 Uncategorised 0
Combination therapy shows superior survival benefit over standard treatment

More: EC approves lazertinib in combination with amivantamab for NSCLC patients
Source: News
